News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

14th Aug 20

Resignation of Non Executive Director Edward Rayner

Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that its non-executive director Mr Edward Rayner has resigned from the Board effective 14 August 2020.

Mr Rayner joined the Pharmaxis Board in conjunction with a share placement to UK based Arix Bioscience plc in September 2018. At the time he was  the investment director leading the Arix investment. Mr Rayner has recently commenced a new executive position with a UK life science technology company, having left Arix earlier this year.

Pharmaxis Chairman Malcolm McComas said, “We will miss Ed’s contribution as an experienced global specialist biotech investor, but we understand his need to focus on his new position and wish him well.”

5th Aug 20

US$7 Million of US Bronchitol Launch Milestone Payment Brought Forward

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced an accelerated timeline on payment of the initial tranche of a US$10 million Bronchitol launch milestone following negotiation with its US licensee Chiesi Farmaceutici S.p.A. (Chiesi). US$7 million of the milestone will now be payable by Chiesi upon US approval of Bronchitol by the Food and Drug Administration (FDA) who have advised a Goal Action Date of 1 November 2020. Another US$3 million will remain payable on shipment by Pharmaxis of commercial launch stock in the first quarter of 2021. 

Read full media release - pdf
23rd Jul 20

Pharmaxis Submits Investigational New Drug (IND) Application for the Treatment of Myelofibrosis

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS), the leading developer of therapeutics targeting lysyl oxidase enzymes to treat fibrosis and cancer, announced it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for a planned phase 1/2 study of PXS-5505 for the treatment of myelofibrosis. The protocol incorporates a one-month dose escalation phase followed by 6 months’ treatment in an open label study of patients who are not on a JAK inhibitor.  The study is planned to commence in Q4 2020 and expected to conclude in 2022.

Read full media release - pdf